Quick Answer
Armata Pharmaceuticals, Inc. reported Total Assets of $76.88 million for the year ending 2025.
- Armata Pharmaceuticals, Inc. showed a decrease of -11.1% in Total Assets from 2024 to 2025.
- This data is from Armata Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $34.35 million | Q2 2014: $31.26 million | Q3 2014: $28.42 million | Q1 2015: $38.60 million | Q2 2015: $36.37 million | Q3 2015: $34.08 million | Q1 2016: $28.26 million | Q2 2016: $29.28 million | Q3 2016: $26.04 million | Q1 2017: $14.30 million | Q2 2017: $15.11 million | Q3 2017: $13.78 million | Q1 2018: $14.40 million | Q2 2018: $11.72 million | Q3 2018: $10.62 million | Q1 2019: $9.62 million | Q2 2019: $34.92 million | Q3 2019: $29.30 million | Q1 2020: $44.10 million | Q2 2020: $49.46 million | Q3 2020: $45.68 million | Q1 2021: $52.85 million | Q2 2021: $48.28 million | Q3 2021: $42.67 million | Q1 2022: $107.77 million | Q2 2022: $100.98 million | Q3 2022: $92.88 million | Q1 2023: $108.78 million | Q2 2023: $101.21 million | Q3 2023: $112.76 million | Q1 2024: $120.36 million | Q2 2024: $108.31 million | Q3 2024: $98.24 million | Q1 2025: $87.25 million | Q2 2025: $80.79 million | Q3 2025: $89.52 million.
- Over the full 13 years of available data (2013 to 2025), Armata Pharmaceuticals, Inc.'s Total Assets has grown by 86.5%.
- Historical annual values: Fiscal year 2025: $76.88 million | Fiscal year 2024: $86.44 million | Fiscal year 2023: $98.36 million | Fiscal year 2022: $95.83 million | Fiscal year 2021: $69.77 million | Fiscal year 2020: $39.52 million | Fiscal year 2019: $25.45 million | Fiscal year 2018: $14.55 million | Fiscal year 2017: $11.14 million | Fiscal year 2016: $18.15 million | Fiscal year 2015: $31.49 million | Fiscal year 2014: $28.62 million | Fiscal year 2013: $41.21 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: